Article
The V654A second-site KIT mutation increases tumor oncogenesis and STAT activation in a mouse model of gastrointestinal stromal tumor.
Oncogene - 1 Dec 2020
Zhang Jennifer Q, Bosbach Benedikt, Loo Jennifer K, Vitiello Gerardo A, Zeng Shan, Seifert Adrian M, Medina Benjamin D, Param Nesteene J, Maltbaek Joanna H, Rossi Ferdinand, Antonescu Cristina R, Besmer Peter, DeMatteo Ronald P
Abstract excerpt
Gastrointestinal stromal tumor (GIST) is the most common human sarcoma and arises in the gastrointestinal tract. Most GISTs are caused by activating mutations in the KIT receptor tyrosine kinase, such as the exon 11 KIT V559Δ mutation. The small molecule imatinib inhibits KIT and has been a mainstay of therapy in GIST. Unfortunately, imatinib-treated patients typically relapse, most often due to clonal emergence...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.